Compare Biogen Inc (BIIB) vs Progressive Corp (PGR) Price & Performance

Biogen IncTrade

Progressive CorpTrade

Price performance (Past 24H)

Key statistics

Biogen Inc vs Progressive Corp — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Progressive Corp trades at $220 (market cap $131.91B). The key difference: Progressive Corp is far larger — about 4.7× Biogen Inc's market cap, and Progressive Corp pays a 6.13% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.

	BIIB	PGR
Market Cap	$28.34B	$131.91B
Sector	Health	Financials
52-Week High	$216.63	$252.68
52-Week Low	$122.68	$190.40
Enterprise Value	$30.62B	$140.14B
Dividend Yield	—	6.13%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Biogen Inc

Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.

The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.

Progressive Corp

Progressive (PGR) trades at $234.48, up 1.63% today, near its consensus price target of $240.89. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and a net income margin of 12.93%. Technical indicators are bullish, with the price above key moving averages. Recent news highlights focus on Q2 2026 earnings expectations due July 15, 2026.

Outlook is positive given earnings growth and analyst buy ratings, but risks include potential earnings misses and competitive pressures. The stock offers value with a P/E of 11.93, below industry averages, supporting a bullish view for long-term investors despite near-term volatility.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BIIB

Biogen names Michael J. Parini as new Chief Legal Officer starting August 3, 2026GlobeNewsWire · 4 hours agoBullish Real-world study shows 83% of early Alzheimer's patients stable or improved on LEQEMBI over 17 monthsPRNewsWire · 1 day agoBullish Biogen's diranersen shows promising Phase 2 results slowing early Alzheimer's decline and reducing tau protein.GlobeNewsWire · 1 day agoBullish View details →

PGR

Progressive reports 4% net income growth in Q2 2026 despite 31% drop in quarterly profit.GlobeNewsWire · 4 hours agoNeutral View details →

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.